Abstracts tagged "Lupus nephritis"

Abstract Number: 1745 • ACR Convergence 2021
Pre-pregnancy Switching from Mycophenolate to Azathioprine in Patients with Lupus Nephritis: A Retrospective Outcome Analysis
Saadia Ali¹, Shirish Sangle², Maha Al Falah³ and David D'Cruz⁴, ¹Guys and St Thomas' Hospital NHS Trust, Epsom, United Kingdom, ²Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom, ³Guys and St Thomas' Hospital NHS Trust, Saudi Arabia, United Arab Emirates, ⁴Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Background/Purpose: Mycophenolate Mofetil is not recommended in pregnancy due to teratogenic effects. A previous small prospective study found that switching from MMF to AZA rarely…
Abstract Number: 0531 • ACR Convergence 2021
Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics
Asmaa AbuMaziad¹, Abhimanyu Amarnani² and Ram Singh³, ¹University of California Los Angeles, Los Angeles, CA, ²Los Angeles County + University of Southern California, Los Angeles, CA, ³University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Lupus nephritis (LN) causes substantial morbidity and mortality. LN is histopathologically divided into six classes, which currently serves as the basis for making treatment…
Abstract Number: 1291 • ACR Convergence 2021
Risk of Bleeding-related Complications After Kidney Biopsy in Patients with Systemic Lupus Erythematosus
Eun Song Kang¹, Ji Seon Oh², Soo Min Ahn¹, Yong Gil Kim¹, Chang-Keun Lee¹, Bin Yoo³ and Seokchan Hong³, ¹Asan Medical Center, Seoul, Republic of Korea, ²Asan Medical Center, Ulsan, Republic of Korea, ³Asan Medical Center, Seoul, South Korea
Background/Purpose: Kidney biopsy is essential for the diagnosis and classification of lupus nephritis in patients with systemic lupus erythematosus (SLE). Even though the risk of…
Abstract Number: 1749 • ACR Convergence 2021
Treatment Patterns in Latin American Patients with Lupus Nephritis over a 20-year Period
Rosana quintana¹, Jose Gomez Puerta², Guillermina Harvey³, Marina Scolnik⁴, Nidia Meras⁵, Cintia Otaduy⁶, Maria Salinas⁷, Valeria Arturi⁸, Maria Sattler⁹, Rosa Serrano Morales¹, Luciana Gonzalez Lucero¹⁰, Wilfredo Grageda¹¹, Nicolas Perez¹², Cecilia Nora Pisoni¹³, Simone Appenzeller¹⁴, Ana Silva¹⁵, Odirlei Andre Monticielo¹⁶, Henrique Moriz¹⁷, Francinne Ribiero¹⁸, Emily Figueiredo Neves Yuki Yuki¹⁹, Edgard Neto²⁰, Iris Guerra²¹, Paula Burgos²², Milena Mimica²³, Gustavo Aroca²⁴, Gabriel Tobon²⁵, Luis Gonzalez²⁶, Gerardo Quintana-López²⁷, Andres Bonfanti²⁴, RAFAEL LOPEZ²⁸, Luis Jara Quezada²⁹, Margarita Portela-Hernandez³⁰, HILDA FRAGOSO LOYO³¹, Luis H Silveira³², Ignacio Garcia-De La Torre³³, Carlos Abud-Mendoza³⁴, Jorge Esquivel-Valerio³⁵, Jonathan Losanto³⁶, Astrid Paats³⁷, JORGE CIEZA CALDERON³⁸, Manuel Ugarte-Gil³⁹, Katiuzka Zuniga Corrales⁴⁰, Roberto Munoz⁴¹, Ernesto Cairoli⁴², Gonzalo Silveira⁴³, Luis Catoggio⁴⁴, Ashley Orillion⁴⁵, Chetan Karyekar⁴⁶, Federico Zazzetti⁴⁷ and Bernardo A. Pons-Estel⁴⁸, ¹Grupo Oroño. Centro Regional de Enfermedades Autoinmunes y Reumaticas (GO-CREAR), Rosario, Argentina, ²Hospital Clinic, University of Barcelona, Barcelona, Spain, ³Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Rosario, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Hospital Italiano de Córdoba, Córdoba, Argentina, ⁶Hospital Córdoba, Cordoba, Argentina, ⁷Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁸Hospital HIGA San Martín, La Plata, Argentina, ⁹Sanatorio Británico, Cordoba, Argentina, ¹⁰Janssen Cilag Farmaceutica SA, Tucuman, Argentina, ¹¹Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, ¹²Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, ¹³CEMIC, Buenos Aires, Argentina, ¹⁴Hospital das Clínicas da Universidade Estadual de Campinas, Campinas, Brazil, ¹⁵UFG, GOIANIA, Goias, Brazil, ¹⁶Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁷Hospital das Clinicas, Universidade Federal de Pernambuco, Pernambuco, Brazil, ¹⁸Hospital Universitario Pedro Ernesto, UERJ, Rio de Janeiro, Brazil, ¹⁹Hospital Das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil, ²⁰UNIFESP, São Paulo, Brazil, ²¹Hospital del Salvador, Santiago, Chile, ²²Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile, ²³Universidad San Sebastián, Santiago, Chile, ²⁴Clínica de la Costa Ltda., Barranquilla, Colombia, ²⁵Fundación Valle del Lili, Cali, Colombia, ²⁶Universidad de Antioquia, Medellin, Colombia, ²⁷Reumavance Group, Rheumatology section, Department of Internal Medicine, Fundación Santa Fe de Bogotá University Hospital; Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia; Department of Internal Medicine, School of Medicine, Universidad de Los Andes, Bogota, Colombia, ²⁸Hospital Luis Vernaza, Guayaquil, Ecuador, ²⁹Centro Médico La Raza, Mexico City DF, Mexico, ³⁰IMSS, Mexico Df, Mexico, ³¹INCMNSZ, Tlalpan, Mexico, ³²Instituto Nacional de Cardiologia, Mexico City, Mexico, ³³Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, ³⁴Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatología y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ³⁵University Hospital Dr. Jose Eleuterio Gonzalez, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³⁶Hospital de Clínicas I, San Lorenzo, Paraguay, ³⁷Hospital de Clinicas, Asuncion, Paraguay, ³⁸Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ³⁹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ⁴⁰Hospital Cayetano Heredia, Lima, Peru, ⁴¹Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, ⁴²Autoimmune Diseases Unit, Centro Asistencial del Sindicato Médico del Uruguay (CASMU) and Hospital Evangélico, Montevideo, Uruguay, ⁴³Hospital Señor del Milagro, Salta, Argentina, ⁴⁴Hospital Italiano de Buenos Aires, Olivos, Argentina, ⁴⁵Global Commercial Strategic Organisation, Johnson and Johnson, Horsham, PA, ⁴⁶Janssen R&D, Spring House, PA, ⁴⁷Medical Affairs, Jan-Cil Argentina, Buenos Aires, Argentina, ⁴⁸Grupo Oroo - Centro Regional de Enfermedades Autoinmunes y Reumticas (GO-CREAR), Rosario, Argentina
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease. Over the last decade, changes have occurred in the treatment of these patients,…
Abstract Number: 0535 • ACR Convergence 2021
Therapeutic Efficacy of a Biomimetic ALXR Agonist in Murine Systemic Lupus Erythematosus (SLE)
Priyal Dave¹, Tiange Dong¹, Andrew Mead¹, Isaac Asante¹, Brandon Ebright¹, Eugene Zhou¹, RIta Li¹, Nicos Petasis¹, William Stohl² and Stan Louie¹, ¹University of Southern California, Los Angeles, CA, ²University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Neutrophils are key initiators and promoters of autoimmunity, including SLE, via the elaboration of neutrophil extracellular traps (NETs). We tested the efficacy of the…
Abstract Number: 1299 • ACR Convergence 2021
Longitudinal Patterns of Response to Standard of Care Therapy for Lupus Nephritis: Data from the Accelerating Medicines Partnership Lupus Network
Peter Izmirly¹, Maria Dall'Era², Kenneth Kalunian³, Kristina Deonaraine¹, Mimi Kim⁴, Philip Carlucci¹, Jessica Li⁵, Andrea Fava⁵, H. Michael Belmont⁶, Chaim Putterman⁷, Jennifer Anolik⁸, Betty Diamond⁹, David Wofsy¹⁰, Diane Kamen¹¹, Judith James¹², Accelerating Medicines Partership (AMP) RA/SLE Network¹³, Deepak Rao¹⁴, The Accelerating Medicines Partnership in SLE Network¹⁵, Michelle Petri¹⁶, Jill Buyon⁶ and Richard Furie¹⁷, ¹New York University School of Medicine, New York, NY, ²University of California San Francisco, Corte Madera, CA, ³UC San Diego, La Jolla, CA, ⁴Albert Einstein College of Medicine, Larchmont, NY, ⁵Johns Hopkins University, Baltimore, MD, ⁶NYU School of Medicine, New York, NY, ⁷Albert Einstein College of Medicine, Bronx, NY, ⁸University of Rochester Medical Center, Rochester, NY, ⁹Northwell Health, Manhasset, NY, ¹⁰University of California San Francisco, San Francisco, CA, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³Brigham and Women's Hospital, Everett, MA, ¹⁴Brigham and Women's Hospital, Boston, MA, ¹⁵Multiple Institutions, Multiple Cities, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Background/Purpose: The Accelerating Medicines Partnership (AMP) Lupus Network was established with the goal of applying novel technologies to the interrogation of blood and tissue samples…
Abstract Number: 1750 • ACR Convergence 2021
Itolizumab, a Novel anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-escalation Study
Kenneth Kalunian¹, Richard Furie², Jai Radhakrishnan³, Vandana Mathur⁴, Krishna Polu⁴, Stephen Connelly⁴, Joel Rothman⁴, Cherie Ng⁴, Leslie Chinn⁵, Maple Fung⁶, Dolca Thomas⁷ and Chaim Putterman⁸, ¹UC San Diego, La Jolla, CA, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Columbia University, New York, NY, ⁴Equillium, Inc., La Jolla, CA, ⁵Equillium, Inc., South San Francisco, CA, ⁶Equillium, Inc., San Diego, CA, ⁷Equillium, Inc., Brooklyn, NY, ⁸Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: CD6, a co-stimulatory receptor predominantly expressed on T cells, promotes CD4+ T cell proliferation and differentiation into Th1/Th17 cells. The CD6 ligand, activated leukocyte…
Abstract Number: 0077 • ACR Convergence 2021
Association of Lupus Nephritis and Other Clinical Features with Antiphospholipid Antibody Positivity Among Patients with Systemic Lupus Erythematosus
Prarthana Jain, Jim Oates, Dulaney Wilson and Diane Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Antiphospholipid antibody (aPL) positivity is associated with elevated risk of thrombosis among patients with SLE, but other clinical associations are less well-known. The goal…
Abstract Number: 0538 • ACR Convergence 2021
Strengthening Nuclear Envelope Ameliorates UVB-triggered Skin Inflammation and Kidney Damage in Lupus Mice
Xing Lyu¹, Minghui Li², Ping L Zhang³, Victoria Werth⁴ and Ming-Lin Liu⁴, ¹Tianjin Medical University General Hospital, Philadelphia, PA, ²Tianjin Medical University General Hospital, Tianjin, China (People's Republic), ³Division of Anatomic Pathology,Beaumont Laboratories, Beaumont Health, Royal Oak, MI, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Ultraviolet B (UVB) exposure triggers lupus flare by worsening skin lesions and systemic symptoms such as lupus nephritis. The effects of UVB-induced skin inflammation…
Abstract Number: 1422 • ACR Convergence 2021
Urinary CD163 Predicts Proliferative Lupus Nephritis in SLE Patients with Proteinuria: A Practical Liquid Biopsy Approach
Andrea Fava¹, Jessica Li¹, Daniel Goldman², Jose Monroy-Trujillo¹, Mohamed G. Atta¹, Derek Fine¹, Jill Buyon³, Joel Guthridge⁴, Judith James⁴, Michelle Petri² and Accelerating Medicines Partership (AMP) RA/SLE Network⁵, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³NYU School of Medicine, New York, NY, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Brigham and Women's Hospital, Everett, MA
Background/Purpose: Diagnosis of lupus nephritis (LN) relies on a kidney biopsy obtained in SLE with proteinuria. Delayed access to kidney biopsies may delay diagnosis and…
Abstract Number: 1751 • ACR Convergence 2021
Voclosporin Is Effective in Achieving Complete Renal Response Across Lupus Nephritis Biopsy Classes: Pooled Data from the AURA-LV and AURORA 1 Trials
Anca Askanase¹, Simrat Randhawa², Laura Lisk³ and Paola Mina-Osorio⁴, ¹Columbia University Medical Center, New York, NY, ²Aurinia Pharmaceuticals Inc., Seattle, WA, ³Aurinia Pharmaceuticals Inc., Victoria, ON, Canada, ⁴Aurinia Pharmaceuticals Inc., New York, NY
Background/Purpose: Voclosporin is a novel calcineurin inhibitor recently approved for the treatment of adult patients with active lupus nephritis in combination with background immunosuppressive therapy.…
Abstract Number: 0233 • ACR Convergence 2021
Feasibility and Acceptability of an Online Intervention for Lupus Self-Management Based on the Transtheoretical Model of Change
Katherine Carpenter¹, Melissa French¹, Sara Balestrieri², Sara Johnson², Sarah Gilman³, Cristina Drenkard⁴, S Sam Lim⁵, Maria Dall'Era⁶, Emily Somers⁷, Suzanna Zick⁸, Victoria Werth⁹, Daniel Wallace¹⁰, Melicent Miller¹ and Mary Crimmings¹, ¹Lupus Foundation of America, Washington, DC, ²Pro-Change Behavior Systems, South Kingstown, RI, ³Wayfinder Health Strategies, Falls Church, VA, ⁴Emory University, Atlanta, GA, ⁵Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁶University of California San Francisco, Corte Madera, CA, ⁷University of Michigan, Ann Arbor, MI, ⁸Department of Family Medicine and Nutritional Sciences, Ann Arbor, MI, ⁹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ¹⁰Cedars-Sinai, Los Angeles, CA
Background/Purpose: The Lupus Foundation of America (LFA) has completed a 5-year cooperative agreement with the CDC to develop and evaluate an online lupus self-management (SM)…
Abstract Number: 0595 • ACR Convergence 2021
Lupus Nephritis Disparities Amongst Hospitalizations in the United States: A National Inpatient Sample Study
Sonia Gupta, Koree Willer, Amir Begovic, Mitch Waters, Laura Tarantino, Olufunmilayo Badejo, Ryan Walters and Theresa Townley, Creighton University School of Medicine, Omaha, NE
Background/Purpose: Black, Hispanic, and Native American populations in the US experience increased morbidity and mortality from systemic lupus erythematosus (SLE), with higher rates and worse…
Abstract Number: 1425 • ACR Convergence 2021
Voclosporin for Lupus Nephritis: Interim Analysis of the AURORA 2 Extension Study
Amit Saxena¹, Christopher Mela² and Antonia Coeshall³, ¹NYU School of Medicine, New York, NY, ²Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ³Aurinia Pharmaceuticals Inc., Rockville
Background/Purpose: Voclosporin, a novel calcineurin inhibitor (CNI), has been tested successfully in 2 pivotal trials in adult patients with lupus nephritis (LN). Previously reported results…
Abstract Number: 1752 • ACR Convergence 2021
Efficacy of Voclosporin in Recent Onset Lupus Nephritis
Meggan Mackay¹, Matt Truman², Nicole England², Vanessa Birardi³ and Paola Mina-Osorio⁴, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Aurinia Pharmaceuticals Inc., Victoria, BC, Canada, ³Aurinia Pharmaceuticals Inc, Rockville, MD, ⁴Aurinia Pharmaceuticals Inc., New York, NY
Background/Purpose: Voclosporin is a novel calcineurin inhibitor recently approved for the treatment of adults with active lupus nephritis (LN) in combination with background immunosuppressive therapy.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.